| 000 | 01821 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513190840.0 | ||
| 264 | 0 | _c19990907 | |
| 008 | 199909s 0 0 eng d | ||
| 022 | _a1420-682X | ||
| 024 | 7 |
_a10.1007/s000180050353 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChabrier, P E | |
| 245 | 0 | 0 |
_aNitric oxide synthases: targets for therapeutic strategies in neurological diseases. _h[electronic resource] |
| 260 |
_bCellular and molecular life sciences : CMLS _cJul 1999 |
||
| 300 |
_a1029-35 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
| 650 | 0 | 4 |
_aAmidines _xpharmacology |
| 650 | 0 | 4 |
_aAmyotrophic Lateral Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBenzylamines _xpharmacology |
| 650 | 0 | 4 |
_aBrain Injuries _xdrug therapy |
| 650 | 0 | 4 |
_aBrain Ischemia _xdrug therapy |
| 650 | 0 | 4 | _aEnzyme Induction |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHuntington Disease _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Neurologic Mutants |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 |
_aNerve Degeneration _xdrug therapy |
| 650 | 0 | 4 |
_aNerve Tissue Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aNervous System Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aNitric Oxide _xadverse effects |
| 650 | 0 | 4 |
_aNitric Oxide Synthase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aNitric Oxide Synthase Type I |
| 650 | 0 | 4 | _aOrgan Specificity |
| 650 | 0 | 4 |
_aPolymethacrylic Acids _xpharmacology |
| 650 | 0 | 4 |
_aPyrazines _xpharmacology |
| 650 | 0 | 4 |
_aThiophenes _xpharmacology |
| 700 | 1 | _aDemerlé-Pallardy, C | |
| 700 | 1 | _aAuguet, M | |
| 773 | 0 |
_tCellular and molecular life sciences : CMLS _gvol. 55 _gno. 8-9 _gp. 1029-35 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s000180050353 _zAvailable from publisher's website |
| 999 |
_c10399823 _d10399823 |
||